Following up on the rumors we have been chasing for two weeks, it appears that staffers at Positron Corporation (OTCBB:POSC) have been busy making arrangements for a soon to be announced press conference.

Yesterday, prices took a hit after a blogger made false and defamatory accusations against not only BioMedReports, but the company as well. This is the second time that the blogger has attacked BioMedReports's and owners of this website intend to take swift and complete legal action against the owner/author of that web site. Thus far, after multiple requests, the author of the website has refused to provide us with his legal contact information so that our legal department can commence those actions.

The fact remains that POSC is an established company that has been in business for over a quarter of a century and that a positive announcement- apparently worthy of a press conference- will be made public in the coming days. Speculation continues that a multi-billion dollar company trading on the NYSE at over $50 per share has taken an interest in the company.

Furthermore, sources at the company tell BioMedReports that pending orders for their FDA approved, Frost and Sullivan award winning imaging system run at least "over one hundred deep."

As we told subscribers two days ago, we fully expect the stock price to see substantial gains (beyond the initial 43% gains seen immediately after our trade alert) as it now appears that the company had positioned itself to be the clear leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related story).

In a letter to shareholders last month, the chairman of the board for the company informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."

It is clear that a positive development worthy of a full press conference (rumored arrangements place it at the Nasdaq MarketSite in New York City) may be officially announced as early as Monday.

If true, naked shorters who took negative positions in the stock will not only have to cover, they will help push the stock price much higher by doing so.

Developing...

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites